Vivus Obesity Pill Wins FDA Panel Nod; NeuroSearch Surges

Vivus Inc. gained the most in 12 years after the company’s pill Qnexa won the backing of a regulatory panel, moving the drug a step closer to gaining U.S. approval as the first new obesity treatment in 13 years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.